Press releases - Ypsomed

mylife YpsoPump bolus delivery via smartphone

08/30/2022 - 7:00am Press Releases Ypsomed Group

Burgdorf – Ypsomed launches bolus delivery from the smartphone on the mylife YpsoPump via the mylife App. This new feature enables mylife YpsoPump users to deliver the bolus insulin conveniently and discreetly via their personal smartphone, without having to interact with the pump itself. Following the early summer launch of automated insulin delivery (AID) via the mylife CamAPS FX App, Ypsomed now offers an additional option for discreet remote bolus delivery to all users. People with diabetes now have the freedom to choose their preferred therapy solution.

Topics:

Innovation & Digital Health

Annual General Meeting of Ypsomed elects new Chairman

06/30/2022 - 7:00am Press Releases Ypsomed Group

Burgdorf – Ypsomed's Annual General Meeting on 29 June 2022 approved all the proposals of the Board of Directors. It elected Gilbert Achermann as the new Chairman of the Board of Directors and Simon Michel as a new member of the Board of Directors. The founder and long-standing Chairman Dr. h.c. Willy Michel was given a ceremonial farewell.

Topics:

Management

Ypsomed successfully completes capital increase

06/24/2022 - 7:00am Ad hoc announcement pursuant to Art. 53 LR

Burgdorf – Ypsomed (SIX: YPSN) has completed the capital increase in the full amount of one million new shares very successfully. The subscription and placement price was set at CHF 122.50 after the expiry of the subscription and placement period, which ended on 23 June 2022 at 12:00 CEST. The issue price corresponds to the volume-weighted average price from 21 to 23 June 2022, until 12:00 noon, with a discount of 2.1%. The capital increase with a transaction volume of CHF 122.5 million met with great interest and was significantly oversubscribed. The new shares are eligible for the dividend payment of 06 July 2022. Zürcher Kantonalbank is the Sole Global Coordinator of this capital increase.

Ypsomed announces details of capital increase

06/14/2022 - 7:00am Ad hoc announcement pursuant to Art. 53 LR

Burgdorf – The Board of Directors of Ypsomed (SIX: YPSN) decided in its meeting on Monday, 13 June 2022, to carry out a capital increase from authorised capital created by the resolution of the Annual General Meeting on Wednesday, 30 June 2021, in the amount of a maximum of 1 million fully paid registered shares with a nominal value of CHF 14.15 each. The new shares will be offered to the existing shareholders at market conditions with a discount expected to be between 2% to 3%, while maintaining the subscription rights. It is envisaged to sell the unsubscribed shares in a free placement. There will be no trading of subscription rights. The new shares will be eligible for the dividend payment of 06 July 2022. Zürcher Kantonalbank is the Sole Global Coordinator of this capital increase.

Ypsomed increases sales by 15.2% and triples its operating profit

05/25/2022 - 7:00am Ad hoc announcement pursuant to Art. 53 LR

Burgdorf – Ypsomed (SIX: YPSN) generated a growth in sales of 15.2% in the financial year 2021/22 compared to the previous year and achieved a consolidated turnover of CHF 464.8 million (previous year: CHF 403.7 million). On its continued growth path, the company trebled its operating result (EBIT) to CHF 28.6 million versus the previous year (previous year: CHF 9.3 million). Compared with the previous year, the net profit increased nearly fourfold to CHF 23.1 million (previous year: CHF 5.8 million). In addition, Ypsomed is planning a capital increase to support the targeted growth.